As main immunotherapeutic options, programmed cell death 1 (PD1), PD1 ligand (PDL-1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression might be served as potential factors for individual selection of treatment with immune checkpoint inhibitors for bladder cancer patients [34, 35]. The gene discussed is CTLA4; the disease is urinary bladder cancer.